Suraksha Diagnostic Ltd

- No explicit mention of any current or planned fundraising through debt or equity was made in the provided transcript. - The focus appears to be on organic and inorganic growth through expansion of centers and possible acquisitions, financed through internal resources. - CAPEX guidance for FY '26 is around Rs. 70 crore, with no indication of requiring external fundraising. - The management indicated they are "too new to the process" regarding dividends and seem focused on stabilizing operations and understanding the public market before considering such moves. - No direct references to raising new funds via IPOs or debt issuance were made during the Q&A or closing remarks.

- Planned CAPEX for FY '26 is around Rs. 70 crore (Ritu Mittal). - CAPEX mainly for opening new centers: 4 big centers (~Rs. 10 Cr each) and 4 small centers (Rs. 1.5-2 Cr each). - Additional CAPEX may depend on PPP centers, but exact numbers unknown due to tender-based process. - Strategic investment includes establishment of MRI at Calcutta Medical College within 90 days. - Investment to build genomic lab, expected to launch soon, enhancing B2B business. - Focus on expanding the network with 15-18 new centers planned in FY '26. - Potential acquisitions in Eastern India considered if they fit quality and price criteria. - Emphasis on technology enhancement and operational efficiency as part of future growth.

- Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. - Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. - Price increases are planned at around 2%-3% every alternate year. - Market share impact from new competitors entering Eastern India has not been seen yet. - Opening 15-18 new centers in FY '26, including 8 centers in the first quarter itself, supports growth. - Expansion plans focused on Eastern India with potential acquisitions if suitable. - Growth also driven by new services such as genomic and fetal medicine tests, expected to scale over 2-3 years. - Mature centers expected to deliver margin expansion due to operating leverage, supporting profitable growth.

- Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. - Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. - Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. - Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. - Business model's strong B2C focus (>93% revenue) supports sustainable margins. - Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. - CAPEX planned at around Rs. 70 Cr for FY '26 for expansion and enhancements. - New service lines like genomic labs and fetal medicine expected to add growth and diversify revenue. - Management confident of better financial performance and improved results over next 1-2 years.

- The company does not provide a specific order book or pending orders figure for PPP (Public-Private Partnership) centers as these are awarded through a tendering process and are uncertain. - They are in the process of establishing an MRI center in Calcutta Medical College within the next 90 days, noted as a significant opportunity. - For the fiscal year 2026, Suraksha plans to add approximately 15-18 new centers. - In the first quarter of FY '26, they have already opened 5 centers and plan to open 3 more shortly, totaling 8 centers. - The company has secured necessary approvals for the majority of proposed centers, indicating a robust pipeline for center openings. - They continue to focus on organic growth primarily in Eastern India with potential for acquisitions if suitable.